Actuate Therapeutics (ACTU) Other Accumulated Expenses (2023 - 2025)

Actuate Therapeutics (ACTU) has reported Other Accumulated Expenses for 3 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other Accumulated Expenses fell 39.76% year-over-year to $3.6 million; the TTM figure through Dec 2025 stood at $3.6 million (down 39.76% YoY), while the FY2025 annual figure was $3.6 million, down 39.76% from the prior year.
• Other Accumulated Expenses eased to $3.6 million in Q4 2025 per ACTU's latest filing, from $4.3 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $6.9 million in Q2 2024 and bottomed at $3.2 million in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $5.0 million across 3 years, with a median of $4.9 million in 2025.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses surged 83.84% — and 2025, when it sank 39.76%.
• Actuate Therapeutics' Other Accumulated Expenses stood at $3.2 million in 2023, then soared by 83.84% to $5.9 million in 2024, then tumbled by 39.76% to $3.6 million in 2025.
• Business Quant data shows ACTU's Other Accumulated Expenses at $3.6 million in Q4 2025, $4.3 million in Q3 2025, and $4.6 million in Q2 2025.